PURPOSE: The homeobox transcription factor PITX2 is a known regulator of mammalian ocular development, and human PITX2 mutations are associated with Axenfeld-Rieger syndrome (ARS). However, the treatment of patients with ARS remains mostly supportive and palliative. METHODS: The authors used molecular genetic, pharmacologic, and embryologic techniques to study the biology of ARS in a zebrafish model that uses transgenes to mark neural crest and muscle cells in the head. RESULTS: The authors demonstrated in vivo that pitx2 is a key downstream target of retinoic acid (RA) in craniofacial development, and this pathway is required for coordinating neural crest, mesoderm, and ocular development. pitx2a knockdown using morpholino oligonucleotides disrupts jaw and pharyngeal arch formation and recapitulates ocular characteristics of ARS, including corneal and iris stroma maldevelopment. These phenotypes could be rescued with human PITX2A mRNA, demonstrating the specificity of the knockdown and evolutionary conservation of pitx2a function. Expression of the ARS dominant negative human PITX2A K50E allele also caused ARS-like phenotypes. Similarly, inhibition of RA synthesis in the developing eye (genetic or pharmacologic) disrupted craniofacial and ocular development, and human PITX2A mRNA partially rescued these defects. CONCLUSIONS: RA regulation of pitx2 is essential for coordinating interactions among neural crest, mesoderm, and developing eye. The marked evolutionary conservation of Pitx2 function in eye and craniofacial development makes zebrafish a potentially powerful model of ARS, amenable to in vivo experimentation and development of potential therapies.
PURPOSE: The homeobox transcription factor PITX2 is a known regulator of mammalian ocular development, and humanPITX2 mutations are associated with Axenfeld-Rieger syndrome (ARS). However, the treatment of patients with ARS remains mostly supportive and palliative. METHODS: The authors used molecular genetic, pharmacologic, and embryologic techniques to study the biology of ARS in a zebrafish model that uses transgenes to mark neural crest and muscle cells in the head. RESULTS: The authors demonstrated in vivo that pitx2 is a key downstream target of retinoic acid (RA) in craniofacial development, and this pathway is required for coordinating neural crest, mesoderm, and ocular development. pitx2a knockdown using morpholino oligonucleotides disrupts jaw and pharyngeal arch formation and recapitulates ocular characteristics of ARS, including corneal and iris stroma maldevelopment. These phenotypes could be rescued with human PITX2A mRNA, demonstrating the specificity of the knockdown and evolutionary conservation of pitx2a function. Expression of the ARS dominant negative human PITX2A K50E allele also caused ARS-like phenotypes. Similarly, inhibition of RA synthesis in the developing eye (genetic or pharmacologic) disrupted craniofacial and ocular development, and human PITX2A mRNA partially rescued these defects. CONCLUSIONS:RA regulation of pitx2 is essential for coordinating interactions among neural crest, mesoderm, and developing eye. The marked evolutionary conservation of Pitx2 function in eye and craniofacial development makes zebrafish a potentially powerful model of ARS, amenable to in vivo experimentation and development of potential therapies.
Authors: Adam G Diehl; Sepideh Zareparsi; Min Qian; Ritu Khanna; Rowena Angeles; Philip J Gage Journal: Invest Ophthalmol Vis Sci Date: 2006-05 Impact factor: 4.799
Authors: Laura A Hale; Alexandra Tallafuss; Yi-Lin Yan; Leana Dudley; Judith S Eisen; John H Postlethwait Journal: Gene Expr Patterns Date: 2006-02-07 Impact factor: 1.224
Authors: Faisal Idrees; Agnes Bloch-Zupan; Samantha L Free; Daniela Vaideanu; Pamela J Thompson; Paul Ashley; Glen Brice; Paul Rutland; Maria Bitner-Glindzicz; Peng T Khaw; Scott Fraser; Sanjay M Sisodiya; Jane C Sowden Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2006-03-05 Impact factor: 3.568
Authors: Rafael E Hernandez; Aaron P Putzke; Jonathan P Myers; Lilyana Margaretha; Cecilia B Moens Journal: Development Date: 2007-01 Impact factor: 6.868
Authors: Richard Mark White; Anna Sessa; Christopher Burke; Teresa Bowman; Jocelyn LeBlanc; Craig Ceol; Caitlin Bourque; Michael Dovey; Wolfram Goessling; Caroline Erter Burns; Leonard I Zon Journal: Cell Stem Cell Date: 2008-02-07 Impact factor: 24.633
Authors: K Kitamura; H Miura; S Miyagawa-Tomita; M Yanazawa; Y Katoh-Fukui; R Suzuki; H Ohuchi; A Suehiro; Y Motegi; Y Nakahara; S Kondo; M Yokoyama Journal: Development Date: 1999-12 Impact factor: 6.868
Authors: Adrienne R Niederriter; Erica E Davis; Christelle Golzio; Edwin C Oh; I-Chun Tsai; Nicholas Katsanis Journal: J Vis Exp Date: 2013-08-24 Impact factor: 1.355
Authors: Paweł Stankiewicz; Tahir N Khan; Przemyslaw Szafranski; Leah Slattery; Haley Streff; Francesco Vetrini; Jonathan A Bernstein; Chester W Brown; Jill A Rosenfeld; Surya Rednam; Sarah Scollon; Katie L Bergstrom; Donald W Parsons; Sharon E Plon; Marta W Vieira; Caio R D C Quaio; Wagner A R Baratela; Johanna C Acosta Guio; Ruth Armstrong; Sarju G Mehta; Patrick Rump; Rolph Pfundt; Raymond Lewandowski; Erica M Fernandes; Deepali N Shinde; Sha Tang; Juliane Hoyer; Christiane Zweier; André Reis; Carlos A Bacino; Rui Xiao; Amy M Breman; Janice L Smith; Nicholas Katsanis; Bret Bostwick; Bernt Popp; Erica E Davis; Yaping Yang Journal: Am J Hum Genet Date: 2017-09-21 Impact factor: 11.025
Authors: Takuto Chiba; Nataliya I Skrypnyk; Lauren Brilli Skvarca; Radostin Penchev; Ke Xin Zhang; Elizabeth R Rochon; Jessica L Fall; Paisit Paueksakon; Haichun Yang; Catherine E Alford; Beth L Roman; Ming-Zhi Zhang; Raymond Harris; Neil A Hukriede; Mark P de Caestecker Journal: J Am Soc Nephrol Date: 2015-06-24 Impact factor: 10.121
Authors: Elisabeth Zieger; Greta Garbarino; Nicolas S M Robert; Jr-Kai Yu; Jenifer C Croce; Simona Candiani; Michael Schubert Journal: Cell Mol Life Sci Date: 2018-01-31 Impact factor: 9.261